It also raised questions about the role of central versus peripheral CB1R in controlling voluntary ethanol intake, and whether CB1R antagonists could also be beneficial in mitigating other AUD features, e.g., endotoxemia or gut permeability. The gene discussed is CNR1; the disease is serum lipopolysaccharide activity.